1736-72-7

Basic information

• Product Name: 1-[4-(TRIFLUOROMETHYL)PHENYL]-2-THIOUREA
• Synonyms: 1-[4-(TRIFLUOROMETHYL)PHENYL]-2-THIOUREA;4-(TRIFLUOROMETHYL)PHENYLTHIOUREA;N-[4-(TRIFLUOROMETHYL)PHENYL]THIOUREA;alpha,alpha,alpha-Trifluoro-p-tolylthiourea;à,à,à-trifluoro-p-tolylthiourea;1-[4-(Trifluoromethyl)phenyl]-2-thiourea 97%;1-[4-(Trifluoromethyl)phenyl]-2-thiourea97%;1-[4-(Trifluoromethyl)phenyl]thiourea
• CAS NO: 1736-72-7
• Molecular Formula: C₈H₇F₃N₂S
• Molecular Weight: 220.21
• Product Categories: Organic Building Blocks;Sulfur Compounds;Thioureas;Building Blocks;Chemical Synthesis;Organic Building Blocks;Sulfur Compounds
• Mol File: 1736-72-7.mol
• Article Data: 21

Chemical Properties

• Melting Point: 142-146 °C
• Boiling Point: 269.9 °C at 760 mmHg
• Flash Point: 117 °C
• Appearance: /
• Density: 1.457 g/cm³
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 12.33±0.70(Predicted)
• BRN: 2695479
• CAS DataBase Reference: 1-[4-(TRIFLUOROMETHYL)PHENYL]-2-THIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(TRIFLUOROMETHYL)PHENYL]-2-THIOUREA(1736-72-7)
• EPA Substance Registry System: 1-[4-(TRIFLUOROMETHYL)PHENYL]-2-THIOUREA(1736-72-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-43
• Safety Statements: 26-36/37
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 1736-72-7(Hazardous Substances Data)

Usage

Uses

[4-(Trifluoromethyl)phenyl]thiourea is a reagent used in the synthesis of pharmaceuticals such as thiourea analogs as inhibitors of UT-A and UT-B transporters as well as 2-aminothiazole sphingosine inhibitors.

Upstream product

• 455-14-1 4-trifluoromethylphenylamine 
• 117174-71-7 N-((4-trifluoromethylphenyl)thiocarbamoyl)benzamide 
• 1147550-11-5 ammonium thiocyanate 
• 90774-69-9 4-aminobenzotrifluoride hydrochloride 
• 333-20-0 potassium thioacyanate 
• 1645-65-4 4-(trifluoromethyl)phenyl isothiocyanate 
• 1226922-10-6 C₆H₁₅N*C₈H₆F₃NS₂ 
• 1430796-50-1 C₈H₆F₃NS₂*C₆H₁₂N₂ 
• 540-72-7 sodium thiocyanide 
• 45943-14-4 benzoyl isothiocyanate 

Downstream Products

• 1645-65-4 4-(trifluoromethyl)phenyl isothiocyanate 
• 1744-07-6 1,3-bis(4-(trifluoromethyl)phenyl)thiourea 
• 119125-43-8 2-Methyl-1-(4-trifluoromethyl-phenyl)-isothiourea; hydriodide 
• 777-12-8 2-amino-6-trifluoromethyl-1,3-benzothiazole 
• 86691-07-8 2-amino-5-(trifluoromethyl)benzenethiol 
• 119125-64-3 N-(4-Trifluoromethyl-phenyl)-morpholine-4-carboxamidine 
• 46914-77-6 1-Guanyl-4-(4-trifluormethyl-phenyl)-thiosemicarbazid 
• 643013-14-3 4-(4-chlorophenyl)-N-(4-(trifluoromethyl)phenyl)thiazol-2-amine 
• 1095824-45-5 C₁₃H₁₁F₃N₂O₂S 
• 696628-76-9 4-(4-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine 
• 1166390-18-6 4-(trifluoromethyl)phenylthiourea acrylamide 
• 1214888-50-2 C₁₈H₁₂ClF₃N₂O₂S 

Relevant articles and documents

Discovery of aminothiazole derivatives as novel human enterovirus A71 capsid protein inhibitors

Enterovirus A71 (EV-A71), one of the major pathogens that causes hand, foot and mouth disease (HFMD), has seriously threatened the health and safety of young children. In this study, aminothiazole derivatives were synthesized and screened against EV-A71 in Rhabdomyosarcoma (RD) cells. The best compound (12s), with a biphenyl group, showed activity against EV-A71 (EC50: 0.27 μM) but also against a series of different human enteroviruses without significant cytotoxicity (CC50 > 56.2 μM). Mechanistic studies including time-of-drug-addition assays, viral entry assays and microscale thermophoresis (MST) experiments, showed that 12s binds to EV-A71 capsid and blocks the binding between the viral protein VP1 and the relevant human scavenger receptor class B member 2 (hSCARB2).

Novel arylimino thiazole compound, preparation method and uses thereof

The present invention relates to a compound with antibacterial synergy activity, a preparation and uses thereof, particularly to a novel arylimino thiazole compound, a preparation method and uses thereof, and specifically discloses a class of compounds represented by a formula (I) or optical isomers, cis-trans isomers or pharmaceutically acceptable salts thereof, a preparation method and uses thereof. The invention further discloses a pharmaceutical composition containing the compound. The compound of the present invention can effectively enhance the antibacterial activity of antibiotics, andcan be used for treating antibiotic-resistant bacteria. The formula (I) is defined in the specification.

Synergism of fused bicyclic 2-aminothiazolyl compounds with polymyxin B against: Klebsiella pneumoniae

A series of fused bicyclic 2-aminothiazolyl compounds were synthesized and evaluated for their synergistic effects with polymyxin B (PB) against Klebsiella pneumoniae (SIPI-KPN-1712). Some of the synthesized compounds exhibited synergistic activity. When 4 μg ml-1 compound B1 was combined with PB, it showed potent antibacterial activity, achieving 64-fold reduction of the MIC of PB. Furthermore, compound B1 showed prominent synergistic efficacy in both concentration gradient and time-kill curves in vitro. In addition, B1 combined with PB also exhibited synergistic and partial synergistic effect against E. coli (ATCC25922 and its clinical isolates), Acinetobacter baumannii (ATCC19606 and its clinical isolates), and Pseudomonas aeruginosa (Pae-1399).